Pharmalittle: lilly's alzheimer's drug slowed cognitive decline; most eu countries back plan to push production of key drugs

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember, there are only a few more days until the weekend arrives. So keep plugging

away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required, so

there is no need to haggle over rebates. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. … A NEW ALZHEIMER’S

TREATMENT DEVELOPED BY ELI LILLY SLOWED THE RATE OF COGNITIVE AND FUNCTIONAL DECLINE IN PATIENTS BY 35% COMPARED TO PLACEBO, PAVING THE WAY FOR A SUBMISSION TO THE U.S. FOOD AND DRUG

ADMINISTRATION AND BOOSTING HOPES FOR A NEW CLASS OF ALZHEIMER’S DRUGS, STAT writes. But the positive outcome of the study involving the drug, called donanemab, could be tempered by the

deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs. The results of the study were reported in a press release and have not yet been reviewed by

outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. A MAJORITY OF EUROPEAN UNION COUNTRIES HAVE RALLIED BEHIND A PROPOSAL TO

CREATE A “CRITICAL MEDICINES ACT” THAT WOULD REPLICATE EUROPEAN EFFORTS TOWARD SELF-RELIANCE IN MICROCHIPS, Politico tells us. The act would encourage production of key medicines, as well as

pharmaceutical ingredients, reducing dependencies on major producers like China and India. The idea is put forward in a position paper drawn up by the Belgian government and backed by 18

other countries, including France and Germany. They noted 40% of all pharmaceutical ingredients globally are sourced from China and production for many of these products is concentrated in

just a handful of manufacturing sites. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS,

NEWSLETTERS, PREMIUM EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe